Park Avenue Securities LLC Has $514,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Park Avenue Securities LLC lowered its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 16.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,785 shares of the medical research company’s stock after selling 559 shares during the quarter. Park Avenue Securities LLC’s holdings in Charles River Laboratories International were worth $514,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Wellington Management Group LLP raised its holdings in Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after buying an additional 3,738,018 shares during the period. State Street Corp raised its holdings in shares of Charles River Laboratories International by 2.0% during the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after acquiring an additional 41,421 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Charles River Laboratories International by 40.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after acquiring an additional 509,163 shares in the last quarter. Earnest Partners LLC boosted its stake in Charles River Laboratories International by 12.4% in the 2nd quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after purchasing an additional 110,725 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Charles River Laboratories International by 6.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company’s stock worth $101,483,000 after purchasing an additional 32,311 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the subject of several recent research reports. Bank of America reduced their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Evercore ISI raised their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. UBS Group reiterated a “neutral” rating and issued a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. The Goldman Sachs Group reduced their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a report on Thursday. Finally, Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They issued a “sell” rating and a $151.00 price target on the stock. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $204.38.

Insider Activity

In related news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Trading Down 0.9 %

CRL stock opened at $166.75 on Friday. Charles River Laboratories International, Inc. has a one year low of $160.85 and a one year high of $275.00. The stock has a market cap of $8.53 billion, a price-to-earnings ratio of 20.87, a price-to-earnings-growth ratio of 5.97 and a beta of 1.38. The company has a fifty day moving average price of $187.21 and a two-hundred day moving average price of $197.51. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.72 EPS. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).